Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Results of a Randomized Study of Clodronate in Treating Cancer-Related Hypercalcemia

Results of a Randomized Study of Clodronate in Treating Cancer-Related Hypercalcemia Abstract To the Editor. —The article by Witte and coworkers1 describing the results of a randomized study of clodronate in treating cancer-related hypercalcemia conveys erroneous information regarding the appearance of acute leukemia among subjects of a recent multicenter study. The authors state "the finding of three cases of acute leukemia in 664 patients, most of whom had received alkylating agents, caused the study sponsor (Proctor & Gamble Co, Cincinnati) to stop this investigation early pending analysis of this potential, but unlikely, treatment-related toxicity."This statement minimizes the potential danger of leukemia developing in consort with clodronate therapy. To begin with, the implication that leukemia occurred because alkylating agents had been given is not well supported by the data. None of the three patients who developed leukemia were known to have ever received alkylating agents. (True, a fourth subject, who was exposed to alkylating agents, had multiple myeloma and developed preleukemia.) References 1. Witte RS, Koeller J, Davis TE, et al: Clodronate: A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med 1987;147:937-939.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Results of a Randomized Study of Clodronate in Treating Cancer-Related Hypercalcemia

Peck, William A.
Archives of Internal Medicine , Volume 147 (11) – Nov 1, 1987
Download PDF
1 page

Results of a Randomized Study of Clodronate in Treating Cancer-Related Hypercalcemia

Abstract

Abstract To the Editor. —The article by Witte and coworkers1 describing the results of a randomized study of clodronate in treating cancer-related hypercalcemia conveys erroneous information regarding the appearance of acute leukemia among subjects of a recent multicenter study. The authors state "the finding of three cases of acute leukemia in 664 patients, most of whom had received alkylating agents, caused the study sponsor (Proctor & Gamble Co, Cincinnati) to stop this...
Loading next page...
 
/lp/american-medical-association/results-of-a-randomized-study-of-clodronate-in-treating-cancer-related-4fUPpFbG5X

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1987 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1987.00370110184032
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. —The article by Witte and coworkers1 describing the results of a randomized study of clodronate in treating cancer-related hypercalcemia conveys erroneous information regarding the appearance of acute leukemia among subjects of a recent multicenter study. The authors state "the finding of three cases of acute leukemia in 664 patients, most of whom had received alkylating agents, caused the study sponsor (Proctor & Gamble Co, Cincinnati) to stop this investigation early pending analysis of this potential, but unlikely, treatment-related toxicity."This statement minimizes the potential danger of leukemia developing in consort with clodronate therapy. To begin with, the implication that leukemia occurred because alkylating agents had been given is not well supported by the data. None of the three patients who developed leukemia were known to have ever received alkylating agents. (True, a fourth subject, who was exposed to alkylating agents, had multiple myeloma and developed preleukemia.) References 1. Witte RS, Koeller J, Davis TE, et al: Clodronate: A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med 1987;147:937-939.Crossref

Journal

Archives of Internal Medicine – American Medical Association

Published: Nov 1, 1987

There are no references for this article.